UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Amendment No. 2)*

Praxis Precision Medicines, Inc.

(Name of Issuer)

<u>Common stock, par value \$0.0001 per share</u>
(Title of Class of Securities)

74006W108 (CUSIP Number)

<u>December 31, 2023</u>
(Date of Event Which Requires Filing of this Statement)

☐ Rule 13d-1(b)				
⊠ Rule 13d-1(c)				
☐ Rule 13d-1(d)				

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 74006W	108		13G		Page 2 of 10 Pages		
1	NAME OF REPORTING PERSONS Sphera Funds Management Ltd.						
2	CHECK T (a) □ (b) ⊠	THE APPROPRIATI	E BOX IF A MEMBER O	F A GROUP (See in	astructions)		
3	SEC USE ONLY						
4	CITIZENS	SHIP OR PLACE O	F ORGANIZATION				
NAME OF	5	SOLE VOTING PO					
NUMBER OF SHARES BENEFICIALLY OWNED BY	6	SHARED VOTING 328,986 (*)					
EACH REPORTING PERSON WITH	7	SOLE DISPOSITI					
	8	SHARED DISPOS 328,986 (*)					
9	AGGREG 328,986 (NEFICIALLY OWNED E	BY EACH REPORTI	NG PERSON		
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions □							
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 3.74% (*) (**)							
12	TYPE OF REPORTING PERSON (See instructions) CO						
	CO						

^(*) The beneficial ownership of the securities reported herein is described in Item 4(a).

^(**) Based on 8,791,877 shares of Common Stock outstanding as of December 31, 2023 (as provided by the Issuer in its Rule 424(b) prospectus, as filed with the SEC on January 12, 2024).

CUSIP No. 74006W1	08		13G	Page 3 of 10 Pages			
1	NAME OF REPORTING PERSONS Sphera Global Healthcare GP Ltd.						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions) (a) □ (b) ⊠						
3	SEC USE ONLY						
4	CITIZENS Israel	SHIP OR PLACE OF ORC					
	5	SOLE VOTING POWER	1				
NUMBER OF SHARES BENEFICIALLY OWNED BY	6	SHARED VOTING POV 328,986 (*)	VER				
EACH REPORTING PERSON WITH	7	SOLE DISPOSITIVE PC	OWER				
	8	SHARED DISPOSITIVE 328,986 (*)	E POWER				
9	REPORTING PERSON						
10	CHECK II	F THE AGGREGATE AM	IOUNT IN ROW (9) EXCLU	DES CERTAIN SHARES (See instructions)			
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 3.74% (*) (**)							
TYPE OF REPORTING PERSON (See instructions) CO							

^(*) The beneficial ownership of the securities reported herein is described in Item 4(a).

^(**) Based on 8,791,877 shares of Common Stock outstanding as of December 31, 2023 (as provided by the Issuer in its Rule 424(b) prospectus, as filed with the SEC on January 12, 2024).

CUSIP No. 74006W1	108		13	G	Page 4 of 10 Pages		
1	NAME OI	F REPORTING P	ERSONS				
	Sphera Global Healthcare Management LP						
2	CHECK T (a) □ (b) ⊠	THE APPROPRIA	TE BOX IF A MEMBER (OF A GROUP (See in	structions)		
3	SEC USE	ONLY					
4	CITIZENS	SHIP OR PLACE	OF ORGANIZATION				
	Israel						
	5	SOLE VOTING	POWER				
NUMBER OF SHARES	6	SHARED VOTI	NG POWER				
BENEFICIALLY		328,986 (*)					
OWNED BY EACH	7	SOLE DISPOSI	TIVE POWER				
REPORTING PERSON WITH							
TERSON WITH	8	SHARED DISP	OSITIVE POWER				
		328,986 (*)					
9	AGGREG	ATE AMOUNT I	BENEFICIALLY OWNED	BY EACH REPORTIN	NG PERSON		
	328,986 (*)						
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)						
11	PERCENT	T OF CLASS REI	PRESENTED BY AMOUN	IT IN ROW 9			
	3.74% (*)	(**)					
12	TYPE OF	REPORTING PE	RSON (See instructions)				
	PN						

^(*) The beneficial ownership of the securities reported herein is described in Item 4(a).

^(**) Based on 8,791,877 shares of Common Stock outstanding as of December 31, 2023 (as provided by the Issuer in its Rule 424(b) prospectus, as filed with the SEC on January 12, 2024).

Name of Issuer: **Item 1.** (a) Praxis Precision Medicines, Inc. (b) Address of Issuer's Principal Executive Offices: 99 High Street, 30th Floor, Boston, MA 02110 Item 2. (a) Name of Person Filing: Sphera Funds Management Ltd. Sphera Global Healthcare GP Ltd. Sphera Global Healthcare Management LP (b) Address of Principal Business Office: Sphera Funds Management Ltd. – 4 Itzak Sade, Building A, 29th Floor, Tel Aviv 6777504, Israel Sphera Global Healthcare GP Ltd. - 4 Itzak Sade, Building A, 29th Floor, Tel Aviv 6777504, Israel Sphera Global Healthcare Management LP – 4 Itzak Sade, Building A, 29th Floor, Tel Aviv 6777504, Israel (c) Citizenship: Sphera Funds Management Ltd. - Israel Sphera Global Healthcare GP Ltd. - Israel Sphera Global Healthcare Management LP – Israel (d) Title of Class of Securities: Common Stock, par value \$0.0001 per share CUSIP Number: (e) 74006W108 Item 3. Not applicable.

(a) <u>Amount beneficially owned</u>:

See row 9 of cover page of each reporting person.

The securities reported herein by Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd. and Sphera Global Healthcare Management LP are beneficially owned as follows:

- 80,645 shares of Common Stock representing a total of 0.92% of the total shares of Common Stock outstanding are held directly by Sphera Global Healthcare Master Fund, which has delegated its investment management authority to Sphera Global Healthcare Management LP (the "Management Company").
- 248,341 shares of Common Stock representing a total of 2.82% of the total shares of Common Stock outstanding, are held directly by Sphera Biotech Master Fund, L.P., which has delegated its investment management authority to the Management Company.

The Management Company is managed, controlled, and operated by its general partner, Sphera Global Healthcare GP Ltd., the shares of which are owned 90% by Sphera Funds Management Ltd.

This Statement shall not be construed as an admission by any of the Reporting Persons that it is the beneficial owner of any of the securities covered by this Statement, and each Reporting Person disclaims beneficial ownership of any such securities. In addition, the Reporting Persons and other entities named in this Schedule 13G may be deemed to constitute a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each of the Reporting Persons and other entities named in this Schedule 13G disclaims the existence of any such group.

(b) Percent of class:

See row 11 of cover page of each reporting person

- (c) Number of shares as to which such person has:
 - (i) Sole power to vote or to direct the vote:

See row 5 of cover page of each reporting person

(ii) Shared power to vote or to direct the vote:

See row 6 of cover page of each reporting person and note in Item 4(a) above

(iii) Sole power to dispose or to direct the disposition of:

See row 7 of cover page of each reporting person

(iv) Shared power to dispose or to direct the disposition of:

See row 8 of cover page of each reporting person and note in Item 4(a) above

Item 9. <u>Notice of Dissolution of Group:</u>

Not applicable.

Item 10. <u>Certification</u>:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 4, 2024

Sphera Funds Management Ltd.

/s/ Adi Hanetz By: Adi Hanetz Title: General Counsel

Sphera Global Healthcare GP Ltd.

/s/ Adi Hanetz By: Adi Hanetz Title: General Counsel

Sphera Global Healthcare Management LP

/s/ Adi Hanetz By: Adi Hanetz Title: General Counsel

EXHIBIT NO. DESCRIPTION

Exhibit 1

Joint Filing Agreement by and among the Reporting Persons (incorporated herein by reference to Exhibit 1 to the Schedule 13G filed on June 22, 2023)